Share on StockTwits

Intercept Pharmaceuticals (NASDAQ:ICPT) has received a consensus rating of “Buy” from the thirteen brokerages that are covering the company, AmericanBankingNews.com reports. Two research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $454.20.

A number of analysts have recently weighed in on ICPT shares. Analysts at Nomura upgraded shares of Intercept Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note on Tuesday, July 29th. They now have a $323.00 price target on the stock. Separately, analysts at Deutsche Bank initiated coverage on shares of Intercept Pharmaceuticals in a research note on Monday, July 14th. They set a “buy” rating and a $395.00 price target on the stock. Finally, analysts at Goldman Sachs initiated coverage on shares of Intercept Pharmaceuticals in a research note on Wednesday, July 2nd. They set a “neutral” rating and a $265.00 price target on the stock.

Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 234.60 on Thursday. Intercept Pharmaceuticals has a one year low of $42.41 and a one year high of $497.00. The stock’s 50-day moving average is $233.5 and its 200-day moving average is $293.0. The company’s market cap is $4.947 billion.

In other Intercept Pharmaceuticals news, CEO Mark Pruzanski sold 10,000 shares of the stock on the open market in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $226.72, for a total value of $2,267,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.